Condition: Advanced Solid Tumor · Refractory Hodgkin Lymphoma · Sponsor: FBD Biologics Limited
The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.
This description comes directly from the study's public registry record.
FBD Clinical · +886-2-27921366 · HCB301-101@hanchorbio.com
Always discuss trial participation with your own doctor first.
| Prisma Health-Upstate | Greenville, South Carolina, United States | Recruiting |
| The First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou, China | Recruiting |
| Zhejiang Provincial Cancer Hospital | Hangzhou, China | Recruiting |
| Xuzhou Central Hospital | Xuzhou, China | Recruiting |
| Yantai Yuhuangding Hospital | Yantai, China | Recruiting |
| Southern Medical University Zhujiang Hospital | Zhujiang, China | Recruiting |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung City, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06487624